Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR106 in Patients With Select Relapsed Advanced Malignancies
NCT05861947Phase 1Terminated
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aur106 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), gastric cancer (GC) and 4 more, sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoints: Optimal Biological Dose at 28 days, Dose Limiting Toxicity at 28 days and 4 more. Started Aug 2023; status: terminated.
02
Drugs
aur106
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)gastric cancer (GC)urothelial carcinoma (UC)kidney cancer
Beyond the preview
Go deeper on NCT05861947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861947.